Renovaro Inc. (NASDAQ:RENB) Major Shareholder Anderson Wittekind William Sells 60,000 Shares of Stock

Renovaro Inc. (NASDAQ:RENBGet Free Report) major shareholder Anderson Wittekind William sold 60,000 shares of the business’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $1.55, for a total value of $93,000.00. Following the transaction, the insider now directly owns 974,275 shares of the company’s stock, valued at $1,510,126.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

  • On Wednesday, July 3rd, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The stock was sold at an average price of $1.51, for a total value of $75,500.00.
  • On Monday, July 1st, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The stock was sold at an average price of $1.56, for a total value of $93,600.00.
  • On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The shares were sold at an average price of $1.50, for a total value of $22,006.50.
  • On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total value of $31,600.00.
  • On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Stock Down 3.8 %

Shares of RENB opened at $1.54 on Tuesday. The stock has a 50 day moving average price of $1.40 and a 200 day moving average price of $2.52. The company has a market capitalization of $227.17 million, a price-to-earnings ratio of -1.97 and a beta of 0.60. Renovaro Inc. has a 52-week low of $0.46 and a 52-week high of $5.25.

Renovaro (NASDAQ:RENBGet Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Renovaro

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Renovaro in the first quarter valued at approximately $46,000. Tidal Investments LLC acquired a new stake in shares of Renovaro in the first quarter valued at approximately $98,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Renovaro by 904.0% in the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after acquiring an additional 3,526,565 shares during the period. 71.41% of the stock is owned by institutional investors and hedge funds.

About Renovaro

(Get Free Report)

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.

Featured Articles

Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter.